Boston Scientific ($BSX) increased its Board from 10 to 12 and appointed Catherine R.
Filed with the SEC on · Summarized by InvestorsBot
Boston Scientific ($BSX) increased its Board from 10 to 12 and appointed Catherine R. Smith and Christophe P. Weber, effective Feb 18, 2026. Company says neither has related-party arrangements. 🏛️ #BoardUpdate #MedTech
Under BSX’s non‑employee director program, each new director will receive a prorated cash retainer ≈ $24,663 (from $125K annual) and a prorated equity award ≈ $42,420 (from $215K annual), vesting at term end; shares set on Mar 2, 2026. $BSX 💼 #CorporateGovernance #Investing
Committee assignments effective Feb 23, 2026: Smith → Audit & Nominating/Gov; Weber → Exec Comp & HR and Risk/Science/Technology. BSX will enter standard indemnification agreements with both. $BSX 👥 #Governance #MedTech